# Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937

> **NCT05244759** · PHASE1 · COMPLETED · sponsor: **Bellus Health Inc. - a GSK company** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** [14C]-BLU-5937

## Key facts

- **NCT ID:** NCT05244759
- **Lead sponsor:** Bellus Health Inc. - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-25
- **Primary completion:** 2020-09-23
- **Final completion:** 2021-03-02
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05244759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05244759, "Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05244759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*